Twenty-One Gene Recurrence Score Assay in BRCA-Associated Versus Sporadic Breast Cancers: Differences Based on Germline Mutation Status
|
|
- Horatio Jonathan Morris
- 5 years ago
- Views:
Transcription
1 Twenty-One Gene Recurrence Score Assay in BRCA-Associated Versus Sporadic Breast Cancers: Differences Based on Germline Mutation Status Payal D. Shah, MD 1 ; Sujata Patil, PhD 2 ; Maura N. Dickler, MD 3 ; Kenneth Offit, MD 4 ; Clifford A. Hudis, MD 3 ; and Mark E. Robson, MD 3,4 BACKGROUND: Biological differences between BRCA-associated breast cancer and sporadic breast cancer may warrant different adjuvant chemotherapy (ACRx) recommendations despite similar phenotypic features. A 21-gene expression profile (Oncotype DX) generates a prognostic recurrence score (RS) that predicts the ACRx benefit in patients with hormone receptor positive breast cancer. No reports describe assay results for BRCA-associated breast cancer. METHODS: A review of Memorial Sloan Kettering Cancer Center databases identified 4908 patients with hormone receptor positive, node-negative breast cancer who underwent Oncotype DX testing between July 2006 and March / carriers (cases) were identified and matched (1:2) by age at diagnosis and tumor size to noncarrier controls. Two-sample nonparametric tests were used to compare the baseline characteristics, RSs, and risk stratification between and patients. Conditional logistic regression was used to assess these differences by mutational status. RESULTS: Fifty mutation-associated cases (19 cases and 31 cases) and 100 controls who were well matched for age (P 5.9) and tumor size (P 5.6) were included. and carriers had similar median RSs (P 5.6) and risk category stratification (P 5.3). The median RS was higher for cases versus controls (24 vs 16; P <.0001). Risk stratification also differed by mutational status (P ). had more high-risk disease (28% vs 7%) and intermediate-risk disease (56% vs 36%) and less low-risk disease (16% vs 57%). were more likely than controls to receive ACRx (74% vs 46%; P 5.002). CONCLUSIONS: Germline BRCA-associated hormone receptor positive breast cancer may be associated with intrinsically less favorable biology. Few affected carriers have RS indicating a clear absence of benefit from ACRx. The increased use of ACRx and benefit from ACRx in BRCA carriers may mitigate otherwise inferior outcomes. Cancer 2016;122: VC 2016 American Cancer Society. KEYWORDS: adjuvant chemotherapy, BRCA, breast cancer, Oncotype DX, recurrence. INTRODUCTION Deleterious germline mutations in and confer an increased risk of breast cancer. Risk reduction strategies 1,2 and novel therapeutic approaches for advanced disease 3-5 have been described for these patients; however, significantly fewer data exist for the optimal management of affected BRCA mutation carriers with early-stage breast cancers. The Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) has clinical validity in predicting the risk of breast cancer recurrence as well as clinical utility in quantifying the benefit of adjuvant systemic therapy in patients with early-stage, hormone-responsive breast cancer. 6,7 The output of this 21-gene expression profile is a recurrence score (RS), which translates into a therapeutically meaningful categorization of risk as low, intermediate, or high. A tumor s RS complements its histopathologic description and, when placed in context with other risk stratification elements, helps to inform the selection of patients appropriate for adjuvant systemic therapy. The BRCA mutation status may be one such relevant risk stratification element BRCA-associated cancers have distinct pathological features 8,11,12 and gene expression profiles 13 in comparison with sporadic cancers. These biological differences may translate into treatment responses different from those for sporadic cancers. Indeed, multiple reports indicate that BRCA-associated tumors demonstrate an enhanced response to chemotherapy, 9,10,14-16 which may, in these patients, abrogate otherwise inferior outcomes. 8,10 Accordingly, different recommendations for adjuvant treatment may be warranted for BRCA mutation carriers and noncarriers with phenotypically similar cancers. Corresponding author: Mark E. Robson, MD, Breast Medicine Service/Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; Fax: (646) ; robsonm@mskcc.org 1 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; 2 Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; 3 Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York; 4 Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York. DOI: /cncr.29903, Received: October 12, 2015; Revised: December 10, 2015; Accepted: December 28, 2015, Published online February 9, 2016 in Wiley Online Library (wileyonlinelibrary.com) 1178 Cancer April 15, 2016
2 Oncotype DX in BRCA Mutation Carriers/Shah et al Intrinsic differences between BRCA-associated and sporadic cancers may be reflected in the results of an assay that quantifies recurrence risk and adjuvant systemic therapy benefit. Although Oncotype DX has been well validated for prognosis and for the prediction of chemotherapy benefit, to our knowledge, it has not been described specifically for breast cancers associated with deleterious BRCA mutations. Here we report what we believe is the first description of assay results for breast cancer patients with germline BRCA mutations versus matched cases without germline alterations. MATERIALS AND METHODS Study Population Institutional review board/privacy board approval was obtained to permit subject identification through a review of electronic medical records. A database query identified all patients with hormone receptor positive, human epidermal growth factor receptor 2 (HER2) unamplified, stage I or II breast cancer diagnosed at Memorial Sloan Kettering between July 2006 and March 2014 whose tumors underwent gene expression profiling with the commercially available 21-gene assay. This query yielded 4908 patients. Among these patients, 613 were noted in the Clinical Genetics Service database or medical record as having been tested for alterations in /, and 50 patients harbored deleterious germline mutations (cases). Controls matched for patient age and tumor size were selected from initial query results in a 2:1 fashion by a single investigator blinded to RSs. The matching parameters were as follows: age within 5 years of diagnosis and tumor size within 0.6 cm. If more than 2 controls were available, the selected controls were closest to the case by year of diagnosis. Data Collection Clinical and pathological data were abstracted from the electronic medical record and included the following: patient age, BRCA testing date and results, date of diagnosis, TNM stage, morphological subtype, histologic grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 amplification status, tumor multifocality, RS, and administration of adjuvant chemotherapy (ACRx; yes or no). All data that were initially obtained via the automated query were confirmed through a manual chart review. Tumor specimens were reviewed by surgical pathology at Memorial Sloan Kettering Cancer Center, and these data, rather than data from local pathology reports, were recorded. The tumor size recorded and used for matching was the diameter of the largest focus of invasive carcinoma. For reports without numerical histological grading, tumors described as poorly differentiated, moderately differentiated, and well differentiated were given grades of 3, 2, and 1, respectfully. When 2 descriptors were used (ie, moderately to poorly differentiated), the recorded grade was the higher of the 2. Gene Expression Profiling In all patients, gene expression profiling was performed in fixed paraffin-embedded tumor tissue by Genomic Health, Inc with the Oncotype DX assay as part of routine clinical care to aid in decisions regarding adjuvant systemic therapy. The assay has been previously described. 6,17 Statistical Methods Patient and clinicopathologic characteristics at diagnosis were compared in 2 sets: 1) a comparison of and with 2-sample nonparametric tests and 2) a comparison of cases and controls with differences assessed with a conditional logistic regression model. This model accounted for the matched pairs design. In sensitivity analyses, 3 subset analyses were performed: 1) excluding a mutation carrier with micrometastatic nodal involvement and her controls, 2) excluding a carrier with low (1%-10%) hormone receptor positivity and her controls, and 3) excluding both patients and their respective controls. To examine whether the relation between RS and case/control status (BRCA carrier/noncarrier status) persisted independently of grade, we conducted 2 secondary analyses. In the first, we included Oncotype DX risk stratification (low, intermediate, or high) and grade (1 1 2 vs 3) as covariates in a multivariate conditional logistic regression. In the second, we analyzed the subset of patients with grade 3 tumors. Two-sided P values less than 5% were considered significant. All analyses were conducted with SAS 9.4. RESULTS Study Population Characteristics The study population included 50 patients with BRCA mutations (19 with mutations and 31 with mutations) as well as 100 matched control patients without known deleterious germline BRCA mutations. One hundred forty-six of the 150 patients included in this analysis underwent testing for deleterious / mutations either as part of their routine clinical care (142 patients) or as part of research protocols (4 patients) at Memorial Sloan Kettering Cancer Center Cancer April 15,
3 TABLE 1. Study Population Characteristics All Patients (n 5 19) (n 5 31) P ( vs ) (n 5 50) Controls (n 5 100) P ( vs Controls) Age, median (range), y 46 (24-62) 43 (31-69) (24-69) 44 (22-70).936 Tumor size, median (range), cm 1.3 ( ) 1.4 ( ) ( ) 1.2 ( ).600 Morphology, No. (%) Invasive ductal 18 (95) 27 (87) 45 (90) 87 (87) Invasive lobular 0 4 (13) 4 (8) 9 (9) Other 1 (5) 0 1 (2) 4 (4) Estrogen receptor, median (range), 90 (5-100) 90 ( ) (5-100) 95 (30-100).051 quantitative % a Progesterone receptor, median (range), 60 (0-100) 55 (0-98) (0-100) 85 (0-100).011 quantitative % a Histologic grade, No. (%) b I (7) II 1 (5) 6 (19) 7 (14) 28 (28) III 18 (95) 22 (71) 40 (80) 54 (54) Multifocal, No. (%) Yes 2 (11) 7 (23) 9 (18) 8 (8) No 17 (89) 24 (77) 41 (82) 92 (92) Adjuvant chemotherapy, No. (%) Yes 11 (58) 26 (84) 37 (74) 46 (46) No 8 (42) 5 (16) 13 (26) 54 (54) a If hormone receptor positivity was reported in the pathology report as a range, the mean was taken. b For the histologic grade, grades 1 and 2 were combined for the analysis; the histologic grade was unavailable for 3 -associated tumors and 11 sporadic tumors. or other institutions. Ninety-six of the 100 control patients had BRCA testing performed with negative results. Four additional control patients had no testing performed but had a low pretest probability for carrying a germline mutation on the basis of their personal and family histories. This included a postmenopausal diagnosis at an age 59 years for all 4 patients; an absence of a family history of breast, ovarian, or other BRCA-associated cancers for 3 patients; and only a mother with breast cancer diagnosed at the age of 70 years for the fourth patient. These patients were not known to be Ashkenazi Jews or members of other known founder populations. Clinical and pathological characteristics are shown in Table 1. The median age of the cases was similar to that of the controls (44.5 and 44; P 5.9), with no significant differences between and mutation carriers. Tumor sizes were also similar between cases and controls (1.4 cm vs 1.2 cm; P 5.6) and between and mutation carriers. Ninety percent of the cases and 87% of the controls had tumors with invasive ductal histology. The median estrogen receptor positivity was 90% for carriers, 90% for carriers, and 95% for controls (P for cases vs controls 5.05). The median progesterone receptor expression was 60% for cases and 85% for controls (P 5.01). were significantly more likely to have histologic grade 3 cancers (P 5.005). The histologic grade was unavailable for 3 -associated tumors and 11 sporadic tumors. All patients had node-negative disease with the exception of 1 patient with a deleterious mutation and micrometastatic lymph node involvement (patient B16). One patient with a deleterious mutation and low (1%-10%) expression of estrogen and progesterone receptors according to immunohistochemistry (patient B33) was included. Comparison of RSs and Risk Stratification in Mutation Carriers Versus Mutation Carriers RS medians and distributions are shown in Table 2. and carriers had similar median RSs (23 vs 24; P 5.6) and risk category stratification (P 5.3). More low-risk tumors were seen in patients with mutations (26%) versus patients with mutations (10%). In both groups of patients, most tumors were intermediate-risk. The 2 groups had similar proportions of tumors categorized as high-risk (26.3% in the group vs 29% in the group). Distribution of RS in Controls The median RS for controls was 16 (range, 3-46). Most RSs for controls were categorized as low-risk (57%) Cancer April 15, 2016
4 Oncotype DX in BRCA Mutation Carriers/Shah et al TABLE 2. Recurrence Scores, Medians, and Distributions All Patients (n 5 19) (n 5 31) P ( vs ) (n 5 50) Controls (n 5 100) P ( vs Controls) Recurrence score, median (range) 23 (12-61) 24 (10-71) (10-71) 16 (3-46) <.0001 Low risk (recurrence score < 18), No. (%) 5 (26.3) 3 (10) (16) 57 (57).0002 Intermediate risk (recurrence score 18 9 (47.4) 19 (61) 28 (56) 36 (36) and 30), No. (%) High risk (recurrence score 31), No. (%) 5 (26.3) 9 (29) 14 (28) 7 (7) remained statistically significant (data not shown). RS remained significantly correlated with the BRCA mutation status in analyses adjusted for grade and hormone receptor status. Among only grade 3 tumors, the RS distribution also remained significantly associated with the BRCA mutation status (P ). Figure 1. Risk stratification by the germline mutation status. The percentages of cases and controls with low-, intermediate-, and high-risk disease are shown. The relative proportions of and mutation carriers in each risk category are also indicated. A minority of controls had high-risk disease (7%), and the remainder had intermediate-risk disease (36%). Comparison of RSs in BRCA Mutation Carriers Versus Noncarriers The median RS was higher for mutation carriers (cases) versus controls (24 vs 16; P <.0001). There was also a statistically significant difference in the distribution of risk stratification based on the BRCA mutation status (P ), as shown in Figure 1. had less low-risk disease (16% vs 57%) than controls. had more intermediate-risk (56% vs 36%) and high-risk disease (28% vs 7%) than controls. Sensitivity Analyses The RS medians and distributions were assessed with the inclusion and exclusion of case B16 and/or case B33 as well as their respective controls individually and together. The difference between carriers and noncarriers in the median RSs and in the risk stratification distributions Administration of ACRx Fifty-eight percent of mutation carriers and 84% of mutation carriers received adjuvant systemic therapy (P 5.054). were significantly more likely to receive ACRx than controls (74% vs 46%; P 5.002). Within risk categories, however, there were no significant differences between cases and controls in proportions receiving chemotherapy (Table 3). DISCUSSION The current report is, to our knowledge, the first description of RSs from gene expression profiles for patients with breast cancers associated with deleterious germline mutations in and. This study also compares these RSs with those from a control group of patients with sporadic breast cancer who were matched to cases by patient age and tumor size. Finally, the study describes rates of chemotherapy administration in the 2 groups overall and stratified by risk category. In this data set, there is a statistically and clinically significant difference in the median RS between mutation carriers and noncarriers and in the risk stratification distributions generated from these scores. These RS differences were reflected in significantly different rates of adjuvant systemic therapy administration in carriers and noncarriers. Because the Oncotype DX assay has demonstrated prognostic validity and predictive utility resulting in its incorporation into clinical decision making, these findings have potentially meaningful implications. In this analysis, BRCA mutation carriers were more likely to have intermediate- or high-risk disease and less likely to have low-risk disease in comparison with Cancer April 15,
5 TABLE 3. Administration of Adjuvant Chemotherapy by Risk Stratification and Germline Mutational Status Low Risk Intermediate Risk High Risk Noncarriers (n 5 7) All BRCA 1 (n 5 14) (n 5 9) (n 5 5) Noncarriers (n 5 36) All BRCA 1 (n 5 28) (n 5 19) (n 5 9) Noncarriers (n 5 57) All BRCA 1 (n 5 8) (n 5 3) (n 5 5) Adjuvant Chemotherapy Yes, No. (%) 1 (20) 1 (33) 2 (25) 14 (25) 6 (67) 16 (84) 22 (79) 25 (69) 4 (80) 9 (100) 13 (93) 7 (100) No, No. (%) 4 (80) 2 (67) 6 (75) 43 (75) 3 (33) 3 (16) 6 (21) 11 (31) 1 (20) 0 (0) 1 (7) 0 (0) Not applicable P for cases vs controls controls. Mutation carriers also had a significantly higher median RS than controls (24 vs 16; P <.0001). These patterns remained unchanged with statistical significance in subset analyses after the exclusion of the 2 borderline cases (patient B16 with micrometastatic lymph node involvement and patient B33 with low positive hormone receptor expression) individually and together. Because this multigene assay is prognostic, these data indicate that BRCA-associated tumors may have intrinsically less favorable biology than sporadic cancers. Furthermore, because this assay is also predictive of the benefit of ACRx, these findings suggest that the presence of a germline BRCA mutation may be a marker for response to ACRx in patients with early-stage, hormone receptor positive breast cancers, and few BRCA mutation carriers have RSs indicative of a clear absence of benefit of adjuvant therapy. These inferences rely on the assumed clinical validity and clinical utility of the assay in BRCA-associated breast cancer, which have not specifically been examined in this subset of patients. Despite the inferior prognoses of BRCA-associated tumors suggested by the multigene assay scores, literaturereported outcomes are similar among affected carriers and noncarriers. 8 It has previously been suggested that the increased chemosensitivity of BRCA-related breast cancers might explain an observed prognosis similar to that of patients with sporadic cancers despite more aggressive tumor phenotypic features. 8,10,14 Goodwin et al 8 found that outcomes were similar for mutation carriers and noncarriers with stage I breast cancer. In their study, as in the current report, a significantly higher proportion of BRCA mutation carriers received adjuvant systemic therapy in comparison with noncarriers, and the authors concluded that BRCA mutation carriers who receive standard adjuvant treatment may fare as well as noncarriers of the same age who present with similar cancers. A 2004 analysis by Robson et al 10 also noted a poorer prognosis for Ashkenazi Jewish women with mutations that was abrogated by ACRx administration. Narod et al 9 noted improved survival in patients with BRCA mutations treated for stage I breast cancer with chemotherapy versus those who did not receive chemotherapy. The mortality difference was not attributable to distinct baseline risk profiles because women who received chemotherapy had larger tumors that were more likely to be estrogen receptor negative. That BRCA carriers may derive a particular benefit from chemotherapy has also been suggested by groups exploring treatment responses in BRCA carriers in the neoadjuvant 14,16,18,19 and metastatic settings. 15,20 Arun et al Cancer April 15, 2016
6 Oncotype DX in BRCA Mutation Carriers/Shah et al found that the status was independently associated with higher pathologic complete response rates after preoperative systemic therapy, although the mutation status was not. Another, smaller report noted an increased rate of pathologic complete response in / mutation carriers versus noncarriers. 16 Kriege et al 15 examined chemosensitivity to first-line metastatic chemotherapy for BRCA-associated breast cancer and found significantly increased chemosensitivity in mutation carriers on the basis of the overall response, progression-free survival, and overall survival as well as a trend toward a better response rate to and clinical benefit from therapy in mutation carriers. Consistent with this, in this series, BRCA-associated breast cancers had higher RSs indicative of unfavorable biology and chemotherapy benefit, and significantly more BRCA mutation carriers than affected noncarriers received ACRx. When it was stratified by risk category, ACRx administration was similar for carriers and noncarriers. That is, a mutation carrier with intermediate-risk disease was not more likely to receive ACRx than a noncarrier with intermediate-risk disease. Taken together, the findings are concordant with the literature in suggesting that increased use of, and benefit from, adjuvant systemic therapy in BRCA mutation carriers may mitigate otherwise inferior outcomes of intrinsically less favorable disease; this accounts for the similar prognoses for carriers and noncarriers reported in the literature. The study population included patients with hormone receptor positive, -associated breast cancers, an important subset on which to report because -associated tumors are more commonly hormone receptor negative. 11 Interestingly, - and - associated tumors have been noted to have different gene expression profiles 13 and disparate chemosensitivity. 15 This study did not find statistically significant differences in terms of RSs in -associated tumors versus -associated tumors. However, a higher proportion of -associated tumors than -associated tumors were low-risk (26% vs 10%). This raises the question whether some of these low-risk tumors in mutation carriers occurred sporadically despite the presence of a germline mutation. Tumor mutational profile and loss-of-heterozygosity data are unavailable to confirm the inactivation of the wild-type allele; therefore, it is not possible to establish with certainty that all tumors in patients with germline BRCA mutations arose because of the underlying predisposition. This study has limitations. First, the distribution of RSs in the control sample is slightly different from that reported in the literature. The proportion of low-risk RSs seen in the control subset is similar to an initial validation of the 21-gene assay. 6 However, the control patient population had more intermediate-risk disease than has been reported in the literature (36% in this series vs 20%- 22% 6,7 and fewer high-risk cancers (7% vs 25%-27% 6,7. In comparison with literature-reported RS distributions, the relative shift of BRCA-associated breast cancers toward intermediate-risk RSs becomes more prominent, whereas the relative shift of BRCA-associated breast cancers toward high-risk RSs becomes less prominent. Second, the sample size was too small to fully allow controlling for the tumor grade, hormone receptor status, and multifocality. The histologic grade in particular is known to correlate with the Oncotype DX RS and, therefore, may be viewed as a potential confounding factor in the current analysis. To address this, a grade-adjusted analysis was performed, and the RS distribution remained significantly associated with the BRCA mutation status. In addition, an examination of only grade 3 tumors similarly yielded a persistent, significant association of the RS with the BRCA mutation status. Furthermore, insofar as these downstream phenotypic features are a reflection of the genomic composition of a tumor, controlling for these factors may not be necessary or beneficial in assessing a biological estimation of recurrence risk and therapeutic benefit. Finally, the analysis included breast tumors as small as 0.3 cm. The National Comprehensive Cancer Network guidelines advocate the use of this multigene assay as a category 2A recommendation when evaluating patients with primary tumors characterized as cm with unfavorable features or >1 cm, and node-negative, hormone receptor positive, and HER2-negative. 21 However, because cases and controls were well matched for tumor size, this is unlikely to significantly affect our overall findings. Because most data concerning the care of BRCA mutation carriers focus on risk management and treatment of advanced disease, these data supplement a relatively limited but clinically pertinent body of literature informing adjuvant systemic therapy decisions in affected mutation carriers. The findings are consistent with prior reports noting a benefit of systemic therapy for BRCAassociated breast cancer. That a relatively small proportion of affected BRCA carriers have low-risk breast cancer indicates that few BRCA carriers with breast cancer have a clear absence of benefit from ACRx. Importantly, the tumor size, estrogen receptor status, and age of diagnosis are not predictive of mortality, 8-10,22 so caution should be Cancer April 15,
7 exercised before one foregoes chemotherapy for BRCAassociated early-stage breast cancers because of reassuring phenotypic features. In sum, these data suggest that, in the absence of gene expression profiling through this validated assay, adjuvant systemic therapy should be strongly considered for BRCA mutation carriers with early-stage, hormone receptor positive breast cancer, as indicated by conventional factors. Although higher RSs for carriers indicate biologically unfavorable disease, higher rates of systemic therapy administration and potentially increased benefit from chemotherapy may account for similar prognoses among affected carriers and noncarriers. Given the available data, we concur with the current recommendations of the National Comprehensive Cancer Network in favor of the use of this multigene assay as an adjunct to other factors to inform ACRx recommendations in patients with early-stage, hormone receptor positive breast cancer, 21 regardless of the germline BRCA mutation status. However, because of the observed differences in RSs and risk stratification between cases and controls and between cases and literature-reported RSs, validation of this 21-gene assay in patients with BRCA-associated breast cancers may be warranted. FUNDING SUPPORT No specific funding was disclosed. CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. REFERENCES 1. Domchek SM, Friebel TM, Singer CF, et al. Association of riskreducing surgery in or mutation carriers with cancer risk and mortality. JAMA. 2010;304: Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007;357: Nathanson KL, Domchek SM. Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med. 2011;62: Tutt A, Robson M, Garber JE, et al. Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with or mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376: Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline /2 mutation. J Clin Oncol. 2015;33: Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351: Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer. J Clin Oncol. 2006;24: Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in and mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30: Narod SA, Metcalfe K, Lynch HT, et al. Should all mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013;138: Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on / mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6:R8-R Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among and mutation carriers: results from the Consortium of Investigators of Modifiers of /2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21: Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving and mutations. J Natl Cancer Inst. 1998;90: Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344: Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29: Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Sensitivity to firstline chemotherapy for metastatic breast cancer in and mutation carriers. J Clin Oncol. 2009;27: Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in /2 related breast cancer. J Med Genet. 2002;39: Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164: Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with -positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28: Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in -positive breast cancer patients. Breast Cancer Res Treat. 2014;147: Kriege M, Jager A, Hooning MJ, et al. The efficacy of taxane chemotherapy for metastatic breast cancer in and mutation carriers. Cancer. 2012;118: National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Version nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 5, Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of and mutations. N Engl J Med. 2007;357: Cancer April 15, 2016
IJC International Journal of Cancer
IJC International Journal of Cancer Short Report Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer Naama Halpern 1, Amir Sonnenblick 2,
More informationBreast Cancer: Basic and Clinical Research 2014:8
Open Access: Full open access to this and thousands of other papers at http://www.la-press.com. Breast Cancer: Basic and Clinical Research Oncotype Dx Results in Multiple Primary Breast Cancers Michael
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationThe Efficacy of Taxane Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
The Efficacy of Taxane Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Mieke Kriege, PhD 1 ; Agnes Jager, MD, PhD 1 ; Maartje J. Hooning, MD, PhD 1 ; Elisabeth Huijskens
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationBreast Cancer Assays of Genetic Expression in Tumor Tissue
Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationTITLE: Influence of Radiotherapy and Tamoxifen on Contralateral Cancer Risk in Women with Hereditary Breast Cancer
AD Award Number: DAMD17-01-1-0325 TITLE: Influence of Radiotherapy and Tamoxifen on Contralateral Cancer Risk in Women with Hereditary Breast Cancer PRINCIPAL INVESTIGATOR: Mark E. Robson, M.D. CONTRACTING
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION. Women who carry a germline mutation in
VOLUME 22 NUMBER 12 JUNE 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian,
More informationOverview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation
Overview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation Dr Niklas Loman PhD MD Consultant oncologist Skåne University Hospital Lund, Suecia Prognosis
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationAbstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50
Abstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50 Garber JE 1, Tung NM 2, Elkin EP 3, Allen BA 3, Singh NA 3, Wenstrup R 3, Hartman AR 3,
More informationOUTCOME DISPARITIES BY AGE AND 21-GENE RECURRENCE SCORE RESULT IN HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER
OUTCOME DISPARITIES BY AGE AND 21-GENE RECURRENCE SCORE RESULT IN HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER Shak S, 1 Miller DP, 1 Howlader N, 2 Gliner N, 1 Howe W, 3 Schussler N, 3 Cronin K, 2 Baehner
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationEffect of Oophorectomy on Survival After Breast Cancer
Research Original Investigation Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, PhD; Henry T. Lynch, MD; William D. Foulkes, MBBS, PhD; Nadine
More informationOncotype DX reveals the underlying biology that changes treatment decisions 37% of the time
Oncotype DX reveals the underlying biology that changes treatment decisions 37% of the time Even when treatment decisions based on traditional measures seem conclusive, Oncotype DX can lead to a different
More informationGene Expression Profiling for Managing Breast Cancer Treatment. Policy Specific Section: Medical Necessity and Investigational / Experimental
Medical Policy Gene Expression Profiling for Managing Breast Cancer Treatment Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationFamilial breast cancer. Part II: Relationships with histology, staging, steroid receptors and serum tumor markers
Journal of BUON 7: 61-65, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Familial breast cancer. Part II: Relationships with histology, staging, steroid receptors and serum
More informationOncotype DX tools User Guide
Oncotype DX tools User Guide This guide provides an overview of the data and quick access to the Oncotype DX tools Oncotype DX tools offers two quantitative calculator tools that may be used together with
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationUpdates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationAccuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer
Accuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer Kaylene J. Ready, MS 1, Kristen J. Vogel, MS 2, Deann P. Atchley, PhD 1, Kristine R. Broglio, MS 1, Kimberly K. Solomon, MBA 1, Christopher
More informationHave you been newly diagnosed with early-stage breast cancer? Have you discussed whether chemotherapy will be part of your treatment plan?
Have you been newly diagnosed with early-stage breast cancer? Have you discussed whether chemotherapy will be part of your treatment plan? This guide is designed to educate newly diagnosed women with early-stage
More informationLearning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose
Breast Cancer Quality Improvement Project with Oncotype DX Denise Johnson Miller, MD, FACS Medical Director Breast Surgery Hackensack Meridian Health Legacy Meridian (Jersey Shore University Medical Center,
More informationClinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country
DOI 10.1007/s00268-009-0146-8 Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country Cheng-Har Yip Æ N. A. Taib Æ W. Y. Choo
More informationSection: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014
Medical Policy Manual Topic: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Date of Origin: October 5, 2004 Section: Genetic Testing Last
More information11th Annual Population Health Colloquium. Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011
11th Annual Population Health Colloquium Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011 Agenda Personalized medicine in oncology healthcare Clinical relevance of personalized
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationCorporate Medical Policy
Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Medical Policy Manual Genetic Testing, Policy No. 42 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Next Review: December 2018 Last Review:
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationOUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
More information-- Kaiser Permanente Presents Results from Large Community-Based Study Consistent with NSABP Recurrence Study Findings
www.genomichealth.com Contacts: Kathleen Rinehart/GHI: 408/460-9116 Jim Weiss/GHI: 415/609-3680 Lori Garvey/NSABP: 412/330-4621 The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationRoadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:7332-7341 Presented by Deming Mi 7/25/2006 Major reasons for few prognostic factors to
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationShe counts on your breast cancer expertise at the most vulnerable time of her life.
HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More information1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45
1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women
More informationReliable Evaluation of Prognostic & Predictive Genomic Tests
Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationThe risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
Gynecologic Oncology 96 (2005) 222 226 www.elsevier.com/locate/ygyno The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers Kelly A. Metcalfe a,b, *, Henry T. Lynch c, Parviz Ghadirian
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationAssociation Between Contralateral Prophylactic Mastectomy and Breast Cancer Outcomes by Hormone Receptor Status
Association Between Contralateral Prophylactic Mastectomy and Breast Cancer Outcomes by Hormone Receptor Status Abenaa M. Brewster, MD, MHS 1 ; Isabelle Bedrosian, MD 2 ; Patricia A. Parker, PhD 3 ; Wenli
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationA Measure of the Quality and Value of Standardized Genomic Testing in an Integrated Health System
A Measure of the Quality and Value of Standardized Genomic Testing in an Integrated Health System A Review From BayCare Health System Claudia Lago Toro, MD Medical Director Shimberg Breast Center St. Joseph
More informationSFMC Breast Cancer Site Study: 2011
SFMC Breast Cancer Site Study: 2011 Introduction Breast cancer is the most frequently diagnosed cancer among American women, except for skin cancers. It is the second leading cause of cancer death in women,
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 1/2019 Origination: 1/2006 Next Review: 9/2019 Policy
More informationPlatinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Sæther et al. Hereditary Cancer in Clinical Practice (2018) 16:9 https://doi.org/10.1186/s13053-018-0092-2 RESEARCH Open Access Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer:
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationFavorable Prognosis in Patients With T1a/T1bN0 Triple-Negative Breast Cancers Treated With Multimodality Therapy
Favorable Prognosis in Patients With T1a/T1bN0 Triple-Negative Breast Cancers Treated With Multimodality Therapy Alice Y. Ho, MD 1 ; Gaorav Gupta, MD, PhD 1 ; Tari A. King, MD 2 ; Carmen A. Perez, MD 1
More informationFinancial Disclosure. Learning Objectives. Use of Genomics in the NCDB, Early Data Analysis. I have no financial disclosures
Use of Genomics in the NCDB, Early Data Analysis Katharine Yao, MD Chief, Division of Surgical Oncology NorthShore University HealthSystem Chair, QI Committee, NAPBC Financial Disclosure I have no financial
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationMEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint )
MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationSummary BREAST CANCER - Early Stage Breast Cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationLinking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care
Linking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care June 16, 2015 NAACCR, Charlotte, NC Ann Hamilton, Ph.D. Keck School of Medicine, University
More informationA new way of looking at breast cancer tumour biology
A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 9/2018 Origination: 1/2006 Next Review: 9/2019 Policy
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2017 Related Policies: None Assays of Genetic Expression in Tumor Tissue as a Technique to Description Laboratory tests have been developed that detect
More informationProstate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review
CASE REPORT Oncology & Hematology https://doi.org/10.3346/jkms.2017.32.2.377 J Korean Med Sci 2017; 32: 377-381 Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationOncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office
Oncotype DX Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10) This overview summarises the key issues
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationAre Small Breast Cancers Good because They Are Small or Small because They Are Good?
The new england journal of medicine Special Report Are Small Breast Cancers Good because They Are Small or Small because They Are Good? Donald R. Lannin, M.D., and Shiyi Wang, M.D., Ph.D. The recent article
More information